Enhancement of the oral bioavailability of breviscapine by nanoemulsions drug delivery system

Drug Development and Industrial Pharmacy

Volumn 41, Issue 2, 2015, Pages 177-182

  Ma, Yan ^a   Li, HaiGang ^a   Guan, ShiXia ^a  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Bioavailability; Breviscapine; Caco 2 cell; Nanoemulsions; Pharmacokinetics

Indexed keywords

BREVISCAPINE; EMULSION; EXCIPIENT; FLAVONOID; HERBACEOUS AGENT; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NONHUMAN; RAT; REVIEW; TRANSCYTOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CACO 2 CELL LINE; EMULSION; ERIGERON; IN VITRO STUDY; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; METABOLISM; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; PERMEABILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRUGS, CHINESE HERBAL; EMULSIONS; ERIGERON; EXCIPIENTS; FLAVONOIDS; HUMANS; IN VITRO TECHNIQUES; INTESTINAL ABSORPTION; NANOTECHNOLOGY; P-GLYCOPROTEIN; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84921923310     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.947510     Document Type: Review

References (21)

1. Jia JH, Chen KP, Chen SX, et al. Breviscapine, a traditional Chinese medicine, alleviates myocardial ischaemia reperfusion injury in diabetic rats. Acta Cardiol 2008;63:757-62.
2. Xiong F, Xiong C, Yao J, et al. Preparation, characterization and evaluation of breviscapine lipid emulsions coated with monooleate-PEG-COOH. Int J Pharm 2011;421:275-82.
3. Wang M, Xie C, Cai RL, et al. Studies on antioxidant activities of breviscapine in the cell-free system. Am J Chinese Med 2008;36: 1199-207.
4. Li XL, Li YQ, Yan WM, et al. A study of the cardioprotective effect of breviscapine during hypoxia of cardiomyocytes. Planta Med 2004;70:1039-44.
5. Lin LL, Liu AJ, Liu JG, et al. Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats. J Cardiovasc Pharm 2007;50:327-32.
6. Xiong Z, Liu C, Wang F, et al. Protective effects of breviscapine on ischemic vascular dementia in rats. Biol Pharm Bull 2006;29: 1880-5.
7. Zhong H, Deng Y, Wang X, Yang B. Multivesicular liposome formulation for the sustained delivery of breviscapine. Int J Pharm 2005;301:15-24.
8. Hao X, Cheng G, Yu JE, et al. Study on the role of hepatic first-pass elimination in the low oral bioavailability of scutellarin in rats. Die Pharmazie 2005;60:477-8.
9. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliver Rev 2012;64:701-5.
10. Ding Y, Huang GH. Formula screening and optimizing for the dispersible tablets of breviscapine by orthogonal experiment. Zhong Yao Cai 2010;33:455-8.
11. Fei X, Chen X, Liang G, et al. Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. J Drug Target 2009;17:408-14.
12. Li M, Zheng Y, Shan FY, et al. Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine. Acta Pharmacol Sin 2013;34:1108-15.
13. Singh B, Bandopadhyay S, Kapil R, et al. Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications. Crit Rev Ther Drug Carrier Syst 2009;26: 427-521.
14. Xia H, Qiu F, Zhu S, et al. Isolation and identification of ten metabolites of breviscapine in rat urine. Biol Pharm Bull 2007;30: 1308-16.
15. Gao F, Zhang Z, Bu H, et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J Control Release 2011;149:168-74.
16. Chen H, Khemtong C, Yang X, et al. Nanonization strategies for poorly water-soluble drugs, Drug Discov Today 2011;16: 354-60.
17. Ganta S, Deshpande D, Korde A, Amiji M. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol 2010;27:260-73.
18. Ma Y, Lin BQ, Li WZ, Hu XF. Studies on absorption kinetics of naringenin in rat intestine. Chin Tradit Patent Med 2012;34:74-7.
19. Fu Q, Sun J, Ai X, et al. Nimodipine nanocrystals for oral bioavailability improvement: role of mesenteric lymph transport in the oral absorption. Int J Pharma 2013;448:290-7.
20. Chhabra G, Chuttani K, Mishra AK, Pathak K. Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Drug Dev Ind Pharm 2011;37:907-16.
21. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharma Res 1997;14:763-6.